Bronx, New York Clinical Trials

A listing of Bronx, New York clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 420 clinical trials
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

neurofibroma
cataract
glioma
schwartz
multiple meningiomas
Memorial Sloan Kettering Cancer Center (Site 210)
 (4.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +16 other locations
Targeted Fortification of Donor Breast Milk in Preterm Infants

This study is a randomized controlled trial comparing standard fortification of donor breast milk to targeted fortification of donor breast milk in preterm infants. The purpose of the study is to determine if there is a benefit to target fortifying donor breast milk in the preterm population. The investigators hypothesize …

Columbia University Medical Center/ New York - Presbyterian
 (1.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

solid tumor
kras
kras g12c mutation
ki-ras
metastatic malignant solid tumor
Memorial Sloan Kettering Cancer Center
 (4.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +7 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

eliglustat
deficiency
imiglucerase
gaucher disease
Investigational Site Number 840005
 (2.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +220 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840110
 (2.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +135 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

gaa gene
glycogen storage disease type ii
deficiency
replacement therapy
myozyme
Investigational Site Number 840005
 (2.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +190 other locations
Fabry Disease Registry & Pregnancy Sub-registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary …

fabry's disease
fabrazyme
alpha-galactosidase
agalsidase beta
deficiency
Investigational Site Number 840080
 (2.4 away) Contact site
  • 0 views
  • 05 Aug, 2024
  • +136 other locations
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of …

parkinson's disease
datscan
genetic testing
resting tremor
bradykinesia
Columbia University Medical Center
 (1.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +45 other locations
An Observational Study on Sarilumab-exposed Pregnancies

Primary Objective: To evaluate the relative risk of major structural birth defects, specifically a pattern of anomalies, in sarilumab-exposed pregnancies compared to disease-matched unexposed pregnancies. Secondary Objective: To evaluate the risk for sarilumab-exposure relative to the group of healthy pregnant women, and the effect of exposure on other adverse pregnancy …

United States
 (8.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Communication Training for Cancer Patients Their Caregivers and Their Doctors

The purpose of this study is to develop and test a new communication intervention, "Values and Options in Cancer Care 2.0" (VOICE 2.0), which involves oncologist training, patient and caregiver coaching, and caregiver support. The VOICE 2.0 intervention was developed by members of the study team to improve communication among …

Memorial Sloan Kettering Cancer Center
 (4.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location